Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Rochet JC"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-13 z 13
    Tytuł:
    TREM2-Deficient Microglia Attenuate Tau Spreading In Vivo.
    Autorzy:
    Lee-Gosselin A; Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
    Jury-Garfe N; Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA.; Department of Anatomy, Cell Biology & Physiology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
    You Y; Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA.; Department of Anatomy, Cell Biology & Physiology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
    Dabin L; Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA.; Department of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
    Soni D; Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA.; Department of Radiology & Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
    Dutta S; Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN 47907, USA.; Purdue Institute for Integrative Neuroscience, Purdue University, West Lafayette, IN 47907, USA.
    Rochet JC; Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN 47907, USA.; Purdue Institute for Integrative Neuroscience, Purdue University, West Lafayette, IN 47907, USA.
    Kim J; Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA.; Department of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
    Oblak AL; Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA.; Department of Radiology & Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
    Lasagna-Reeves CA; Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA.; Department of Anatomy, Cell Biology & Physiology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.; Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
    Pokaż więcej
    Źródło:
    Cells [Cells] 2023 Jun 10; Vol. 12 (12). Date of Electronic Publication: 2023 Jun 10.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
    MeSH Terms:
    Alzheimer Disease*/genetics
    Alzheimer Disease*/pathology
    Tauopathies*/pathology
    Membrane Glycoproteins/genetics ; Microglia/metabolism ; Receptors, Immunologic/genetics ; Signal Transduction ; tau Proteins/genetics ; tau Proteins/metabolism ; Animals ; Mice
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Two C-terminal sequence variations determine differential neurotoxicity between human and mouse α-synuclein.
    Autorzy:
    Landeck N; Brain Repair and Imaging in Neural Systems, Department of Experimental Medical Science, Lund University, Lund, Sweden.
    Strathearn KE; Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, USA.; Present address: Fujifilm Irvine Scientific, Santa Ana, CA, USA.
    Ysselstein D; Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, USA.; Present address: Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
    Buck K; Brain Repair and Imaging in Neural Systems, Department of Experimental Medical Science, Lund University, Lund, Sweden.; Present address: AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany.
    Dutta S; Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, USA.; Purdue Institute for Integrative Neuroscience, Purdue University, West Lafayette, IN, USA.
    Banerjee S; Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA.
    Lv Z; Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA.; Present address: Bruker Nanosurfaces Division, Goleta, Santa Barbara, CA, USA.
    Hulleman JD; Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, USA.; Present address: Departments of Ophthalmology and Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
    Hindupur J; Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, USA.; Present address: Liveon Biolabs Pvt. Ltd., Tumakuru, Karnataka, India.
    Lin LK; School of Materials Engineering, Purdue University, West Lafayette, IN, USA.
    Padalkar S; School of Materials Engineering, Purdue University, West Lafayette, IN, USA.; Present address: Department of Mechanical Engineering, Iowa State University, Ames, IA, USA.
    Stanciu LA; School of Materials Engineering, Purdue University, West Lafayette, IN, USA.
    Lyubchenko YL; Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA.
    Kirik D; Brain Repair and Imaging in Neural Systems, Department of Experimental Medical Science, Lund University, Lund, Sweden. .
    Rochet JC; Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, USA. .; Purdue Institute for Integrative Neuroscience, Purdue University, West Lafayette, IN, USA. .
    Pokaż więcej
    Źródło:
    Molecular neurodegeneration [Mol Neurodegener] 2020 Sep 08; Vol. 15 (1), pp. 49. Date of Electronic Publication: 2020 Sep 08.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Protein Aggregation, Pathological*/pathology
    alpha-Synuclein/*chemistry
    alpha-Synuclein/*toxicity
    Animals ; Humans ; Mice ; Neurons/pathology ; Rats ; Rats, Sprague-Dawley
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Novel Small Molecules Targeting the Intrinsically Disordered Structural Ensemble of α-Synuclein Protect Against Diverse α-Synuclein Mediated Dysfunctions.
    Autorzy:
    Tóth G; Elan Pharmaceuticals, 700 Gateway Boulevard, South San Francisco, CA, 94080, USA.; Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK.; MTA-TTK-NAP B - Drug Discovery Research Group - Neurodegenerative Diseases, Institute of Organic Chemistry, Research, Center for Natural Sciences, Hungarian Academy of Sciences, 1245, Budapest, Hungary.; Cantabio Pharmaceuticals, 1250 Oakmead Pkwy, Sunnyvale, CA, 94085, USA.
    Neumann T; NovAliX: Building B: Biology BioParc, bld Sébastien Brant BP 30170, F-67405, Illkirch Cedex, France.
    Berthet A; Gladstone Institute of Neurological Disease, San Francisco, CA, 94158, USA.
    Masliah E; Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.; Division of Neurosciences and Molecular Neuropathology Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
    Spencer B; Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.
    Tao J; Howard Hughes Medical Institute and Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, 94158, USA.
    Jobling MF; Elan Pharmaceuticals, 700 Gateway Boulevard, South San Francisco, CA, 94080, USA.
    Gardai SJ; Elan Pharmaceuticals, 700 Gateway Boulevard, South San Francisco, CA, 94080, USA.
    Bertoncini CW; Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK.; IBR - Instituto de Biología Molecular y Celular de Rosario, National Scientific and Technical Research Council, Buenos Aires, Argentina.; Laboratory of Molecular Biophysics, Institute for Research in Biomedicine, Baldiri Reixac 10, 08028, Barcelona, Spain.
    Cremades N; Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK.
    Bova M; Elan Pharmaceuticals, 700 Gateway Boulevard, South San Francisco, CA, 94080, USA.
    Ballaron S; Elan Pharmaceuticals, 700 Gateway Boulevard, South San Francisco, CA, 94080, USA.
    Chen XH; Elan Pharmaceuticals, 700 Gateway Boulevard, South San Francisco, CA, 94080, USA.
    Mao W; Elan Pharmaceuticals, 700 Gateway Boulevard, South San Francisco, CA, 94080, USA.
    Nguyen P; Howard Hughes Medical Institute and Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, 94158, USA.
    Tabios MC; Howard Hughes Medical Institute and Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, 94158, USA.
    Tambe MA; Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, USA.
    Rochet JC; Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, USA.; Purdue Institute for Integrative Neuroscience, Purdue University, West Lafayette, IN, USA.
    Junker HD; NovAliX: Building B: Biology BioParc, bld Sébastien Brant BP 30170, F-67405, Illkirch Cedex, France.; Aalen University (Hochschule Aalen), Beethovenstraße 1, 73430, Aalen, DE, Germany.
    Schwizer D; NovAliX: Building B: Biology BioParc, bld Sébastien Brant BP 30170, F-67405, Illkirch Cedex, France.
    Sekul R; NovAliX: Building B: Biology BioParc, bld Sébastien Brant BP 30170, F-67405, Illkirch Cedex, France.
    Ott I; NovAliX: Building B: Biology BioParc, bld Sébastien Brant BP 30170, F-67405, Illkirch Cedex, France.
    Anderson JP; Elan Pharmaceuticals, 700 Gateway Boulevard, South San Francisco, CA, 94080, USA.
    Szoke B; Elan Pharmaceuticals, 700 Gateway Boulevard, South San Francisco, CA, 94080, USA.
    Hoffman W; Elan Pharmaceuticals, 700 Gateway Boulevard, South San Francisco, CA, 94080, USA.
    Christodoulou J; Institute of Structural & Molecular Biology, University College London, Gower Street, London, WC1E 6BT, UK.
    Yednock T; Elan Pharmaceuticals, 700 Gateway Boulevard, South San Francisco, CA, 94080, USA.
    Agard DA; Howard Hughes Medical Institute and Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, 94158, USA.
    Schenk D; Elan Pharmaceuticals, 700 Gateway Boulevard, South San Francisco, CA, 94080, USA.; Prothena Biosciences Inc, 331 Oyster Point Blvd, South San Francisco, CA, 94080, USA.
    McConlogue L; Elan Pharmaceuticals, 700 Gateway Boulevard, South San Francisco, CA, 94080, USA. .; Gladstone Institute of Neurological Disease, San Francisco, CA, 94158, USA. .; Howard Hughes Medical Institute and Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, 94158, USA. .
    Pokaż więcej
    Źródło:
    Scientific reports [Sci Rep] 2019 Nov 18; Vol. 9 (1), pp. 16947. Date of Electronic Publication: 2019 Nov 18.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Small Molecule Libraries/*pharmacology
    alpha-Synuclein/*metabolism
    Amyloid/antagonists & inhibitors ; Amyloid/metabolism ; Cell Line ; Fluorescence Resonance Energy Transfer ; High-Throughput Screening Assays/methods ; Humans ; Intrinsically Disordered Proteins/metabolism ; Phagocytosis/drug effects ; Protein Folding ; Small Molecule Libraries/chemistry ; Small Molecule Libraries/toxicity ; Surface Plasmon Resonance ; alpha-Synuclein/chemistry ; alpha-Synuclein/drug effects
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease.
    Autorzy:
    Mittal S; Neurogenomics Laboratory and Parkinson Personalized Medicine Program, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.; Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA.
    Bjørnevik K; Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.; The Norwegian Multiple Sclerosis Competence Center, Department of Neurology, Haukeland University Hospital, Norway.
    Im DS; Brain and Mind Research Institute, Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario K1H 8M5, Canada.
    Flierl A; The Parkinson's Institute and Clinical Center, Sunnyvale, CA 94085, USA.
    Dong X; Neurogenomics Laboratory and Parkinson Personalized Medicine Program, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.; Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA.
    Locascio JJ; Neurogenomics Laboratory and Parkinson Personalized Medicine Program, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.; Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA.
    Abo KM; Neurogenomics Laboratory and Parkinson Personalized Medicine Program, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.
    Long E; Neurogenomics Laboratory and Parkinson Personalized Medicine Program, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.
    Jin M; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.; Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA.
    Xu B; Department of Pharmacology, University of California at Davis, Davis, CA 95616, USA.
    Xiang YK; Department of Pharmacology, University of California at Davis, Davis, CA 95616, USA.
    Rochet JC; Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN 47907, USA.
    Engeland A; Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.; Department of Pharmacoepidemiology, Norwegian Institute of Public Health, Oslo, Norway.
    Rizzu P; German Center for Neurodegenerative Diseases (DZNE), Tübingen 72076, Germany.
    Heutink P; German Center for Neurodegenerative Diseases (DZNE), Tübingen 72076, Germany.
    Bartels T; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.; Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA.
    Selkoe DJ; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.; Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA.
    Caldarone BJ; Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA.; Harvard NeuroDiscovery Center, Harvard Medical School, Boston, MA 02115, USA.
    Glicksman MA; Harvard NeuroDiscovery Center, Harvard Medical School, Boston, MA 02115, USA.
    Khurana V; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.; Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA.; Harvard Stem Cell Institute, Cambridge, MA 02138, USA.
    Schüle B; The Parkinson's Institute and Clinical Center, Sunnyvale, CA 94085, USA.
    Park DS; Brain and Mind Research Institute, Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario K1H 8M5, Canada.
    Riise T; Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.; The Norwegian Multiple Sclerosis Competence Center, Department of Neurology, Haukeland University Hospital, Norway.
    Scherzer CR; Neurogenomics Laboratory and Parkinson Personalized Medicine Program, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA. .; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.; Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA.
    Pokaż więcej
    Źródło:
    Science (New York, N.Y.) [Science] 2017 Sep 01; Vol. 357 (6354), pp. 891-898.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
    MeSH Terms:
    Gene Expression Regulation*/drug effects
    Parkinson Disease/*ethnology
    Parkinson Disease/*genetics
    Receptors, Adrenergic, beta-2/*metabolism
    alpha-Synuclein/*genetics
    Acetylation ; Adrenergic beta-1 Receptor Agonists/pharmacology ; Adrenergic beta-Antagonists/pharmacology ; Adrenergic beta-Antagonists/therapeutic use ; Albuterol/pharmacology ; Albuterol/therapeutic use ; Animals ; Cell Line, Tumor ; Enhancer Elements, Genetic ; Histones/metabolism ; Humans ; Ligands ; Mice ; Neuroprotective Agents/pharmacology ; Norway/ethnology ; Parkinson Disease/drug therapy ; Promoter Regions, Genetic ; Propranolol/pharmacology ; Propranolol/therapeutic use ; Receptors, Adrenergic, beta-2/genetics ; Risk ; Substantia Nigra/metabolism ; Transcription, Genetic/drug effects
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    A novel pathway for amyloids self-assembly in aggregates at nanomolar concentration mediated by the interaction with surfaces.
    Autorzy:
    Banerjee S; Department of Pharmaceutical Sciences, University of Nebraska Medical Center, 986025 Nebraska Medical Center, Omaha, NE 68198-6025, USA.
    Hashemi M; Department of Pharmaceutical Sciences, University of Nebraska Medical Center, 986025 Nebraska Medical Center, Omaha, NE 68198-6025, USA.
    Lv Z; Department of Pharmaceutical Sciences, University of Nebraska Medical Center, 986025 Nebraska Medical Center, Omaha, NE 68198-6025, USA.
    Maity S; Department of Pharmaceutical Sciences, University of Nebraska Medical Center, 986025 Nebraska Medical Center, Omaha, NE 68198-6025, USA.
    Rochet JC; Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana, USA.; Purdue Institute for Integrative Neuroscience, Purdue University, West Lafayette, Indiana, USA.
    Lyubchenko YL; Department of Pharmaceutical Sciences, University of Nebraska Medical Center, 986025 Nebraska Medical Center, Omaha, NE 68198-6025, USA.
    Pokaż więcej
    Źródło:
    Scientific reports [Sci Rep] 2017 Mar 30; Vol. 7, pp. 45592. Date of Electronic Publication: 2017 Mar 30.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
    MeSH Terms:
    Amyloid beta-Peptides/*metabolism
    Protein Aggregation, Pathological/*metabolism
    Amyloid beta-Peptides/chemistry ; Microscopy, Atomic Force ; Molecular Dynamics Simulation ; Signal Transduction ; Surface Properties ; alpha-Synuclein/metabolism
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Endosulfine-alpha inhibits membrane-induced α-synuclein aggregation and protects against α-synuclein neurotoxicity.
    Autorzy:
    Ysselstein D; Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, USA.; Purdue Institute for Integrative Neuroscience, Purdue University, West Lafayette, IN, USA.
    Dehay B; Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France.; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France.
    Costantino IM; Department of Neurology, Massachusetts Alzheimer's Disease Research Center, Massachusetts General Hospital, Charlestown, MA, USA.
    McCabe GP; Department of Statistics, Purdue University, West Lafayette, IN, USA.
    Frosch MP; Department of Neurology, Massachusetts Alzheimer's Disease Research Center, Massachusetts General Hospital, Charlestown, MA, USA.
    George JM; Department of Biological and Experimental Psychology, School of Biological and Chemical Sciences, Queen Mary University of London, London, UK.
    Bezard E; Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France.; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France.
    Rochet JC; Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, USA. .; Purdue Institute for Integrative Neuroscience, Purdue University, West Lafayette, IN, USA. .
    Pokaż więcej
    Źródło:
    Acta neuropathologica communications [Acta Neuropathol Commun] 2017 Jan 10; Vol. 5 (1), pp. 3. Date of Electronic Publication: 2017 Jan 10.
    Typ publikacji:
    Journal Article; Multicenter Study
    MeSH Terms:
    Cell Membrane/*drug effects
    Neuroprotective Agents/*pharmacology
    Peptides/*pharmacology
    Protein Aggregation, Pathological/*drug therapy
    alpha-Synuclein/*drug effects
    Adenoviridae ; Aged ; Aged, 80 and over ; Animals ; Brain/drug effects ; Brain/metabolism ; Brain/pathology ; Cell Membrane/metabolism ; Cells, Cultured ; Cohort Studies ; Dopaminergic Neurons/drug effects ; Dopaminergic Neurons/metabolism ; Dopaminergic Neurons/pathology ; Escherichia coli ; Female ; HEK293 Cells ; Humans ; Intercellular Signaling Peptides and Proteins ; Lewy Body Disease/metabolism ; Lewy Body Disease/pathology ; Male ; Middle Aged ; Neuroprotective Agents/metabolism ; Peptides/metabolism ; Protein Aggregation, Pathological/metabolism ; Rats, Sprague-Dawley ; Recombinant Proteins/drug effects ; Recombinant Proteins/genetics ; Recombinant Proteins/metabolism ; Unilamellar Liposomes/chemistry ; alpha-Synuclein/genetics ; alpha-Synuclein/metabolism
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease.
    Autorzy:
    Tóth G; Department of Chemistry, University of Cambridge, Cambridge, United Kingdom ; Elan Pharmaceuticals, South San Francisco, California, United States of America.
    Gardai SJ; Elan Pharmaceuticals, South San Francisco, California, United States of America.
    Zago W; Elan Pharmaceuticals, South San Francisco, California, United States of America.
    Bertoncini CW; Department of Chemistry, University of Cambridge, Cambridge, United Kingdom ; SEDIPFAR (Servicio De Descubrimiento, Diseño Y Desarrollo Pre-Clínico De Fármacos De La Argentina) drug discovery platform, Universidad Nacional de Rosario, Rosario, Argentina.
    Cremades N; Department of Chemistry, University of Cambridge, Cambridge, United Kingdom.
    Roy SL; Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana, United States of America.
    Tambe MA; Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana, United States of America.
    Rochet JC; Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana, United States of America.
    Galvagnion C; Department of Chemistry, University of Cambridge, Cambridge, United Kingdom.
    Skibinski G; Gladstone Institute of Neurological Disease, San Francisco, California, United States of America ; Taube-Koret Center for Neurodegenerative Disease Research, The Consortium for Frontotemporal Dementia Research, and The Hellman Family Foundation Program for Alzheimer's Disease Research, San Francisco, California, United States of America.
    Finkbeiner S; Gladstone Institute of Neurological Disease, San Francisco, California, United States of America ; Taube-Koret Center for Neurodegenerative Disease Research, The Consortium for Frontotemporal Dementia Research, and The Hellman Family Foundation Program for Alzheimer's Disease Research, San Francisco, California, United States of America ; Departments of Neurology and Physiology, UCSF, San Francisco, California, United States of America.
    Bova M; Elan Pharmaceuticals, South San Francisco, California, United States of America.
    Regnstrom K; Elan Pharmaceuticals, South San Francisco, California, United States of America.
    Chiou SS; Elan Pharmaceuticals, South San Francisco, California, United States of America.
    Johnston J; Elan Pharmaceuticals, South San Francisco, California, United States of America.
    Callaway K; Elan Pharmaceuticals, South San Francisco, California, United States of America.
    Anderson JP; Elan Pharmaceuticals, South San Francisco, California, United States of America.
    Jobling MF; Elan Pharmaceuticals, South San Francisco, California, United States of America.
    Buell AK; Department of Chemistry, University of Cambridge, Cambridge, United Kingdom.
    Yednock TA; Elan Pharmaceuticals, South San Francisco, California, United States of America.
    Knowles TP; Department of Chemistry, University of Cambridge, Cambridge, United Kingdom.
    Vendruscolo M; Department of Chemistry, University of Cambridge, Cambridge, United Kingdom.
    Christodoulou J; Department of Structural & Molecular Biology, University College London, London, United Kingdom.
    Dobson CM; Department of Chemistry, University of Cambridge, Cambridge, United Kingdom.
    Schenk D; Elan Pharmaceuticals, South San Francisco, California, United States of America.
    McConlogue L; Elan Pharmaceuticals, South San Francisco, California, United States of America.
    Pokaż więcej
    Źródło:
    PloS one [PLoS One] 2014 Feb 14; Vol. 9 (2), pp. e87133. Date of Electronic Publication: 2014 Feb 14 (Print Publication: 2014).
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Molecular Targeted Therapy*
    Intrinsically Disordered Proteins/*antagonists & inhibitors
    Parkinson Disease/*drug therapy
    Small Molecule Libraries/*pharmacology
    Small Molecule Libraries/*therapeutic use
    alpha-Synuclein/*antagonists & inhibitors
    Animals ; Binding Sites ; Dopaminergic Neurons/drug effects ; Dopaminergic Neurons/metabolism ; Dopaminergic Neurons/pathology ; Humans ; Intrinsically Disordered Proteins/chemistry ; Intrinsically Disordered Proteins/metabolism ; Mice ; Models, Biological ; Models, Molecular ; Nerve Degeneration/metabolism ; Nerve Degeneration/pathology ; Parkinson Disease/pathology ; Phagocytes/drug effects ; Phagocytes/metabolism ; Synapses/drug effects ; Synapses/metabolism ; alpha-Synuclein/chemistry ; alpha-Synuclein/metabolism
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Effect of spermidine on misfolding and interactions of alpha-synuclein.
    Autorzy:
    Krasnoslobodtsev AV; Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
    Peng J
    Asiago JM
    Hindupur J
    Rochet JC
    Lyubchenko YL
    Pokaż więcej
    Źródło:
    PloS one [PLoS One] 2012; Vol. 7 (5), pp. e38099. Date of Electronic Publication: 2012 May 25.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
    MeSH Terms:
    Spermidine/*pharmacology
    alpha-Synuclein/*chemistry
    Humans ; Microscopy, Atomic Force ; Protein Folding/drug effects ; Protein Multimerization/drug effects ; alpha-Synuclein/metabolism
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity.
    Autorzy:
    Gitler AD; Whitehead Institute for Biomedical Research and Howard Hughes Medical Institute, Cambridge, Massachusetts 02142, USA.
    Chesi A
    Geddie ML
    Strathearn KE
    Hamamichi S
    Hill KJ
    Caldwell KA
    Caldwell GA
    Cooper AA
    Rochet JC
    Lindquist S
    Pokaż więcej
    Źródło:
    Nature genetics [Nat Genet] 2009 Mar; Vol. 41 (3), pp. 308-15. Date of Electronic Publication: 2009 Feb 01.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Study
    MeSH Terms:
    Drug Resistance/*genetics
    Epistasis, Genetic/*physiology
    Manganese/*toxicity
    Proton-Translocating ATPases/*genetics
    Saccharomyces cerevisiae Proteins/*genetics
    alpha-Synuclein/*physiology
    Animals ; Caenorhabditis elegans/drug effects ; Caenorhabditis elegans/genetics ; Cells, Cultured ; Conserved Sequence ; Epistasis, Genetic/drug effects ; Gene Regulatory Networks/genetics ; Gene Regulatory Networks/physiology ; Mutation/physiology ; Neurons/drug effects ; Neurons/metabolism ; Parkinson Disease/etiology ; Parkinson Disease/genetics ; Proton-Translocating ATPases/metabolism ; Proton-Translocating ATPases/physiology ; Saccharomyces cerevisiae/genetics ; Saccharomyces cerevisiae Proteins/metabolism ; Saccharomyces cerevisiae Proteins/physiology ; Tissue Distribution ; alpha-Synuclein/genetics ; alpha-Synuclein/metabolism ; alpha-Synuclein/toxicity
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease.
    Autorzy:
    Outeiro TF; Alzheimer's Research Unit, MGH, Harvard Medical School, CNY 114, 16th Street, Charlestown, MA 02129, USA.
    Kontopoulos E
    Altmann SM
    Kufareva I
    Strathearn KE
    Amore AM
    Volk CB
    Maxwell MM
    Rochet JC
    McLean PJ
    Young AB
    Abagyan R
    Feany MB
    Hyman BT
    Kazantsev AG
    Pokaż więcej
    Źródło:
    Science (New York, N.Y.) [Science] 2007 Jul 27; Vol. 317 (5837), pp. 516-9. Date of Electronic Publication: 2007 Jun 21.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Furans/*pharmacology
    Parkinson Disease/*drug therapy
    Parkinson Disease/*physiopathology
    Quinolines/*pharmacology
    Sirtuins/*antagonists & inhibitors
    Sirtuins/*metabolism
    alpha-Synuclein/*metabolism
    Acetylation ; Animals ; Animals, Genetically Modified ; Cell Death/drug effects ; Cell Line, Tumor ; Cells, Cultured ; Disease Models, Animal ; Dopamine/physiology ; Dose-Response Relationship, Drug ; Drosophila melanogaster ; Humans ; Models, Molecular ; Neurons/cytology ; Neurons/drug effects ; Parkinson Disease/metabolism ; Parkinson Disease/pathology ; Protein Conformation ; RNA, Small Interfering/genetics ; Rats ; Sirtuin 1 ; Sirtuin 2 ; Sirtuins/chemistry ; Sirtuins/genetics ; Transfection ; Tubulin/metabolism ; alpha-Synuclein/genetics
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models.
    Autorzy:
    Cooper AA; School of Biological Sciences, University of Missouri-Kansas City, Kansas City, MO 64110, USA.
    Gitler AD
    Cashikar A
    Haynes CM
    Hill KJ
    Bhullar B
    Liu K
    Xu K
    Strathearn KE
    Liu F
    Cao S
    Caldwell KA
    Caldwell GA
    Marsischky G
    Kolodner RD
    Labaer J
    Rochet JC
    Bonini NM
    Lindquist S
    Pokaż więcej
    Źródło:
    Science (New York, N.Y.) [Science] 2006 Jul 21; Vol. 313 (5785), pp. 324-8. Date of Electronic Publication: 2006 Jun 22.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Protein Transport*
    Endoplasmic Reticulum/*metabolism
    Golgi Apparatus/*metabolism
    Neurons/*physiology
    Parkinsonian Disorders/*physiopathology
    alpha-Synuclein/*metabolism
    rab1 GTP-Binding Proteins/*metabolism
    Animals ; Animals, Genetically Modified ; Caenorhabditis elegans ; Cell Survival ; Cells, Cultured ; Disease Models, Animal ; Dopamine/physiology ; Drosophila ; Gene Expression ; Gene Library ; Humans ; Mice ; Nerve Degeneration ; Neurons/cytology ; Parkinsonian Disorders/metabolism ; Parkinsonian Disorders/pathology ; Proteasome Endopeptidase Complex/metabolism ; Protein Folding ; Proteins/chemistry ; Proteins/metabolism ; Rats ; Recombinant Fusion Proteins/metabolism ; Saccharomyces cerevisiae/genetics ; Saccharomyces cerevisiae/metabolism ; Saccharomyces cerevisiae Proteins/genetics ; Saccharomyces cerevisiae Proteins/metabolism ; alpha-Synuclein/chemistry ; alpha-Synuclein/genetics ; rab GTP-Binding Proteins/genetics ; rab GTP-Binding Proteins/metabolism ; rab1 GTP-Binding Proteins/genetics
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.
    Autorzy:
    Conway KA; Center for Neurologic Diseases, Brigham and Women's Hospital, Department of Neurology, Harvard Medical School, 65 Landsdowne Street, Cambridge, MA 02139, USA.
    Rochet JC
    Bieganski RM
    Lansbury PT Jr
    Pokaż więcej
    Źródło:
    Science (New York, N.Y.) [Science] 2001 Nov 09; Vol. 294 (5545), pp. 1346-9.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
    MeSH Terms:
    Dopamine/*metabolism
    Nerve Tissue Proteins/*chemistry
    Nerve Tissue Proteins/*metabolism
    Animals ; Antioxidants/pharmacology ; Biopolymers/chemistry ; Biopolymers/metabolism ; Catecholamines/pharmacology ; Cytoplasm/metabolism ; Dopamine/chemistry ; Dopamine/pharmacology ; Humans ; Levodopa/pharmacology ; Nerve Tissue Proteins/genetics ; Nerve Tissue Proteins/isolation & purification ; Oxidation-Reduction ; Oxidative Stress ; Parkinson Disease/etiology ; Parkinson Disease/metabolism ; Parkinson Disease/therapy ; Quinones/metabolism ; Spectrometry, Fluorescence ; Synaptic Vesicles/metabolism ; Synucleins ; alpha-Synuclein
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
      Wyświetlanie 1-13 z 13

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies